Neuralink

• 2025-06-02 - Series E - $650M - Neuralink raises $650 million Series E

  source: neuralink.com

• ARK Invest - Participant - Angel / Individual - 1 funding event - first seen 2025-06-02
• DFJ Growth - Participant - VC - 1 funding event - first seen 2025-06-02
• Founders Fund - Participant - VC - 1 funding event - first seen 2025-06-02
• G42 - Participant - Unknown - 1 funding event - first seen 2025-06-02
• Human Capital - Participant - VC - 1 funding event - first seen 2025-06-02
• Lightspeed - Participant - Unknown - 1 funding event - first seen 2025-06-02
• Qatar Investment Authority - Participant - Unknown - 1 funding event - first seen 2025-06-02
• QIA - Participant - Unknown - 1 funding event - first seen 2025-06-02
• Sequoia Capital - Participant - VC - 1 funding event - first seen 2025-06-02
• Thrive Capital - Participant - VC - 1 funding event - first seen 2025-06-02
• Valor Equity Partners - Participant - VC - 1 funding event - first seen 2025-06-02
• Vy Capital - Participant - VC - 1 funding event - first seen 2025-06-02

• DJ Seo - Co-Founder, President and COO

Events

• 2026-04-30 - Capability - Neuralink details surgical robot automation for implant procedure

  Neuralink published a video describing its surgical robot work for automating key steps in receiving a Neuralink implant. The company framed the robot as improving safety, reliability, and scalability for implant procedures. The update reinforces the R1 surgical robot as a core enabling system for Neuralink's clinical BCI platform rather than a standalone surgical robot product.

  Source
• 2026-04-29 - Capability - Neuralink participant controls robotic arm through CONVOY study

  Alex Conley, the second Neuralink participant, used the N1 Implant to control a robotic arm at Barrow Neurological Institute. The robotic arm work is part of Neuralink's CONVOY study, which explores BCI control of assistive devices in real-world use. The update marks Neuralink's clearest recent robotics milestone beyond digital cursor control, but it remains a clinical feasibility study rather than a commercial assistive-robot deployment.

  Source
• 2026-01-01 - Market Signal - Neuralink targets high-volume implant production and automated surgical procedures

  Neuralink targeted high-volume production of its brain-computer interface devices beginning in 2026. The same report described a planned transition toward fully automated surgical implantation procedures. The update links Neuralink's implant scale-up to automation around a robot-assisted medical workflow.

  Source
• 2025-06-02 - Funding - Neuralink raises $650 million Series E

  ARK Invest, DFJ Growth, Founders Fund, G42, Human Capital, Lightspeed, QIA, Sequoia Capital, Thrive Capital, Valor Equity Partners and Vy Capital participated. Neuralink linked the financing to broader access for people with unmet medical needs and continued brain-interface development. At the announcement, Neuralink reported five people with severe paralysis using its technology and clinical trials spanning the United States, Canada and the UAE.

  Source
• 2024-11-24 - Regulatory - Neuralink launches CONVOY feasibility study for robotic arm control

  Neuralink received approval and launched CONVOY, a feasibility study extending N1 Implant control to an assistive robotic arm. CONVOY is designed to evaluate whether people with paralysis can use the N1 Implant to control external robotic assistance. The study expands Neuralink's device-control work from computer interfaces toward physical assistive machines.

  Source
• 2024-11-01 - Regulatory - Neuralink receives Health Canada approval for CAN-PRIME Study

  Neuralink received Health Canada approval to launch CAN-PRIME, its first international clinical trial. CAN-PRIME extends evaluation of the N1 Implant and R1 Robot system outside the United States. The trial studies safety and early effectiveness of Neuralink's implant and surgical robot system.

  Source
• 2024-09-01 - Regulatory - Neuralink receives FDA Breakthrough Device Designation for Blindsight

  The visual prosthesis program is intended to restore visual perception for people with severe vision loss. The designation supports faster development and review but does not represent market approval.

  Source
• 2024-04-12 - Capability - Neuralink reports PRIME Study progress after first human implant

  Neuralink published a progress update on the PRIME Study after the first human implantation. The company said the participant was using the implant to control a computer cursor and digital interfaces. Neuralink also disclosed that some implant threads had retracted from the brain, reducing electrode effectiveness and prompting software and signal-processing changes.

  Source
• 2024-01-29 - Deployment - Neuralink reports first human implant in PRIME Study

  Neuralink announced that the first human participant had received its brain-computer interface implant. The PRIME Study evaluates both the wireless implant and the surgical robot used for implantation. The milestone marked Neuralink's first human use of its implantable BCI system.

  Source
• 2023-09-19 - Regulatory - Neuralink opens recruitment for first-in-human PRIME Study

  Neuralink opened recruitment for its first-in-human PRIME Study at its first hospital site. The study targets people with quadriplegia due to cervical spinal cord injury or amyotrophic lateral sclerosis. Neuralink described the study as evaluating the investigational N1 Implant and R1 Robot system.

  Source
• 2023-05-01 - Regulatory - Neuralink receives FDA approval to launch first-in-human PRIME Study

  Neuralink received FDA approval in May 2023 to launch its first-in-human PRIME Study. The study evaluates the safety and initial effectiveness of the N1 Implant and R1 surgical robot system for people with paralysis. The approval moved Neuralink from preclinical development into human clinical testing for its implantable brain-computer interface.

  Source

Relationships

• Barrow Neurological Institute

  Clinical Study Site - Barrow Neurological Institute conducts Neuralink clinical work including participant robotic-arm control.